Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells and Antibodies in Drug Discovery Europe 2018

Stem Cells and Antibodies in Drug Discovery Europe 2018 Agenda

Human Stem Cell-Derived Renal Cells and High-Throughput Nephrotoxicity Prediction

Jacqueline Chuah, Lab Officer, Institute of Bioengineering and Nanotechnology, A*Star

The kidney is a major target for compound-induced toxicity. Animal-free alternative methods are required by governmental agencies and various industries to decrease costs and increase the throughput of nephrotoxicity prediction. We have developed the first accurate and pre-validated in vitro models for predicting compound-induced nephrotoxicity in humans (Loo and Zink, 2017; Chuah and Zink, 2017; Kandasamy et al., 2015; Li et al., 2014; Li et al., 2013; Su et al., 2014; Su et al., 2016). Our models include the first and only pre-validated and predictive stem cell-based renal in vitro models (Li et al., 2014; Kandasamy et al., 2015; Chuah and Zink, 2017). The most advanced of these models is based on induced pluripotent stem cell (iPS)-derived renal proximal tubular (PTC)-like cells. A rapid one-step protocol has been established for the generation of PTC-like cells in 8 days of differentiation, and these cells can be directly used for compound screening (Kandasamy et al., 2015). Alternatively, PTC-like cells can be applied after cryopreservation. By combining iPS-derived renal cell-based assays with machine learning methods, a test balanced accuracy of 87% could be achieved with respect to nephrotoxicity prediction (Kandasamy et al., 2015; Chuah and Zink, 2017). In addition, underlying mechanisms of drug-induced cellular injury could be correctly identified. We have also established a high-content screening (HCS) platform that combines high-content imaging of renal cells with automated phenotypic profiling and machine learning methods (Su et al., 2016). The automated HCS platform has a test balanced accuracy ranging between 82%-89%, depending on the human renal cell type used (Su et al., 2016; Loo and Zink, 2017). Based on these technologies we are currently developing a portfolio of platforms for the prediction of compound-induced toxicity to various organs. In addition, a kidney-on-chip platform for repeated dose testing is under development. This platform appears to be suitable for the assessment of the human dose response.